Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,291 across all filing types
Latest filing 2019-05-07 AGM Information
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
2019年第一次临时股东大会文件
AGM Information Classification · 95% confidence The document is titled as the "2019 First Extraordinary General Meeting (EGM) Documents" of Autobio Diagnostics Co., Ltd. It contains detailed meeting agenda, meeting procedures, and two specific proposals to be voted on by shareholders: one regarding guarantees for a wholly-owned subsidiary and another regarding business transfer to a secondary subsidiary. The document includes procedural rules, voting methods, and legal opinions related to the EGM. There is no financial statement or earnings data presented, nor is it a transcript or presentation. It is clearly a set of meeting materials for a shareholders' meeting, specifically an extraordinary general meeting, not an annual general meeting. The content aligns with materials typically provided for shareholder meetings to inform and solicit votes on corporate matters. Therefore, the document fits best into the category of AGM Information (AGM-R), which includes presentations and materials shared during general meetings (including extraordinary meetings). The document length (5573 characters) and detailed content confirm it is the meeting materials themselves, not just an announcement of a meeting or report publication.
2019-05-07 Chinese
使用闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the progress of cash management using idle funds. It details the company's purchase and management of various financial products such as open-ended wealth management products, structured deposits, and fixed deposits. The document includes specific dates, amounts, and product details but does not contain comprehensive financial statements or analysis. The length is about 2610 characters, which is relatively short and the content is focused on updating shareholders and the public about ongoing financing activities related to cash management. This fits the description of a Capital/Financing Update (CAP) rather than a full financial report or regulatory filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2019-05-06 Chinese
使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a progress announcement regarding the use of idle raised funds for cash management by the company. It details the amounts invested in financial products, purchase and redemption dates, and earnings from these investments. The document is relatively short (1130 characters) and focuses on updates about the company's financing activities related to raised funds. It does not contain comprehensive financial statements or annual/quarterly report data, nor is it a certification or voting result. The content fits best under Capital/Financing Update (CAP) as it provides updates on the company's use of capital raised and related financial management activities.
2019-05-06 Chinese
关于取得医疗器械注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of medical device registration certificates from a regulatory authority. It includes details about the certificates, product descriptions, R&D investment, market context, and potential impact on company performance. The document is short (1638 characters) and does not contain financial statements or detailed financial data. It is an official announcement about a regulatory approval rather than a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-04-30 Chinese
2019年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2019 年第一季度报告' which translates to '2019 First Quarter Report'. It contains detailed financial statements including consolidated balance sheets, profit and loss statements, cash flow statements, and notes for the first quarter of 2019. The report includes actual financial data, comparisons with prior periods, and management explanations of financial changes. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content and structure align with an Interim / Quarterly Report, which is a comprehensive financial report for a period shorter than a full fiscal year. There is no indication that this is an annual report, audit report, or other filing types. Therefore, the correct classification is Interim / Quarterly Report (IR). Q1 2019
2019-04-29 Chinese
第三届董事会第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board of directors meeting of Zhengzhou Antu Biological Engineering Co., Ltd. It details the meeting date, attendance, voting results, and decisions made, including approval of the 2019 Q1 report and other corporate matters. The text does not contain the actual quarterly financial report or detailed financial data but references that the 2019 Q1 report is disclosed on the Shanghai Stock Exchange website. The document is primarily about board meeting decisions and announcements rather than the report itself. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of board decisions and management matters.
2019-04-29 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.